anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prevent the generation of deformation by heat or force or deformation with age during transportation by using a low-temp. thermoplastic resin which has a specific softening point and is solid at a room temp. CONSTITUTION:The low-temp. thermoplastic resin to be used in the dental mushbite method is the resin which softens at the temp. of hot water or warm water, i.e., 40-100 deg.C and solidifies at a room temp. and is no longer deformed at room temp. A lactone resin which is one of the low-temp. thermoplastic resins is preferably of about 10,000-100,000mol.wt. in order to be used for the dental mushbite method. The resin is liquid or waxy at ordinary temp. and is, therefore, not suitable for the purpose of use if the mol.wt. is <10,000. Conversely, the resin having >=100,000mol.wt. has a high viscosity at the time of melting and the exact transfer of the mold of the rugged shape for the detailed part of the surface of the tooth bed is difficult with such resin. The lactone resins may also be used by blending plural kinds of different grades. The characteristics of the resin formed by blending plural kinds of the different grades have the better bending strength, etc., even if the softening temp. thereof is the same as the softening temp. of the resin of the single grade.
The invention relates to shampoo without silicone oil, cationic polymer, sulfate and preservative and a preparation method thereof, and the shampoo is prepared from the following raw materials: 5-15% of methyl cocoyl sodium taurate, 5-15% of sodium lauryl amphoacetate, 5-30% of sodium lauroyl sarcosinate, 0.1-2% of citric acid, 0.5-4% of an amino acid thickener, 0.05-0.4% of tea tree oil, 0.1-2% of menthocanone, 1-5% of 1, 2-pentanediol, 2-20% of a hair conditioner, 0.5-10% of PEG-80 sorbitan laurate and the balance of water. The invention does not contain irritant, harmful or depositable chemical components such as silicone oil, cationic polymer, sulfate, preservative and the like. The product prepared by the specific process has stable quality, is clear and transparent, has natural tea fragrance, and does not need to be additionally added with pigment and essence. The product has moderate cleaning and washing ability, and can prevent hair dryness due to excessive degreasing, and hair is smooth and easy to comb. The product is mild, non-irritant, rich and fine in foam, easy to wash, light, moist, free of burden, antistatic, safe and degradable. Is suitable for hair and fur with various characteristics, has no anaphylactic reaction after being used, and has great application prospect.
VARITHENA is a drug/device combination product that generates injectable foam. The injectable foam is composed of a liquid and gas phase, both of which are necessary to have its therapeutic effect. VARITHENA is intended to act as follows: (1) the foam displaces blood from the vein to be treated, and (2) the polidocanol then scleroses the endothelium.

The active pharmaceutical ingredient of VARITHENA is polidocanol, a non-ionic surfactant sclerosing agent. The hydrophobic pole of the polidocanol molecule attaches to the lipid cell membrane of the venous endothelium, resulting in disruption of the osmotic barrier, destruction of the venous endothelium, and vasospasm. Following exposure to polidocanol, the interior surface of the vein becomes thrombogenic, which leads to thrombus formation and venous occlusion. The occluded vein is eventually replaced by fibrous connective tissue. Polidocanol is deactivated upon contact with blood, thus limiting the sclerosant action to the endothelium near the site of injection.
A method for processing paramagnetic particle-bound cells, comprises: flowing a cell suspension comprising paramagnetic particle-bound cells and unbound cells through a flow-through magnetic separation/debeading module 8 to separate the paramagnetic particle-bound cells from the unbound cells; flowing a portion of the cell suspension that includes the paramagnetic particle-bound cells through a return loop 14 upstream of the flow-through magnetic separation/debeading module; and flowing the portion of the cell suspension that includes the paramagnetic particle-bound cells through the flow-through magnetic separation/debeading module to debead the paramagnetic particle-bound cells. The cell suspension may further comprise free paramagnetic particles, wherein flowing the cell suspension through the magnetic separation/debeading module separates the free paramagnetic particles and the unbound cells. The cell suspension may be flowed laminarly through the magnetic separation/debeading module. The flow chamber can comprise a magnetic inlet (62b, Fig. 4C) through which any paramagnetic particles enter the flow chamber; a non-magnetic inlet (62a, Fig. 4C); a magnetic outlet (64a; Fig. 4C) opposite the non-magnetic inlet; and a non-magnetic outlet (64b, Fig. 4C) opposite the magnetic inlet, wherein the zero gradient line (58, Fig. 4C) directs all paramagnetic particles and any bound cells to the magnetic outlet.
The utility model relates to a system for treatment of orthodontic anomalies which will find application in dentistry and dental medicine and in particular will serve to digitize the work process in dental practice in the production of orthodontic aligners and the placement of orthodontic implants. The system for treatment of orthodontic anomalies comprises functionally connected multiple dental chairs (1), which are connected to a plurality of digital intraoral cameras (2) for taking digital impressions and at least one X-ray apparatus (3). At least one of the dental chairs (1) is equipped with an electronic device with orthodontic software for planning the aligners and surgical guides (1.1) and a surgical motor (1.2) for placement of orthodontic implants. At least one of the digital intraoral cameras (2) is connected via a server with digital impression transfer software (4) to the electronic device with orthodontic software for planning the aligners and surgical guides (1.1). The electronic device with orthodontic software for planning the aligners and surgical guides (1.1) is connected to a 3D printer (5) with a module for making dental models (5.1) and a module for making surgical guides (5.2). The 3D printer (5) has a functional connection to a vacuum forming machine for the production of aligners (6). An implant navigation subsystem (7) is functionally connected to the surgical motor (1.2) for the placement of orthodontic implants, including an infrared camera (7.1), an electronic device with implant software (7.2) and an implant tip (7.3) having a bur and optic sensors. A dental computer tomograph (8) is connected to the electronic device with implant software (7.3).
Bone cement implantation syndrome (BCIS) is a critical and potentially life-threatening condition that manifests during implantation. Characterized by a constellation of symptoms, including hypoxemia, hypotension, cardiac arrhythmias, elevated pulmonary vascular resistance, and occasionally cardiac arrest, BCIS typically ensues shortly after cement introduction, albeit with rare instances of delayed onset. Primarily attributed to the exothermic reaction of bone cement implantation, this syndrome is caused by local tissue damage, histamine and prostaglandin release, and microemboli formation, ultimately triggering a systemic immune response that culminates in respiratory and circulatory failure. The current hypotheses regarding BCIS include embolism, allergic reactions, and cement autotoxicity. BCIS management emphasizes preventative strategies, encompassing meticulous patient risk assessment, comprehensive preoperative and intraoperative evaluations, and precise cement application techniques. Treatment primarily involves symptomatic therapy and life-support measures to address the systemic effects of the syndrome.
Cerebral microbleeds（CMBs） is a subclinical lesion caused by microvascular disease in the brain, characterized by microleakage of blood. About 30% of ischemic stroke patients, 40% of the healthy people over 80 years old, and 60% of intracranial hemorrhage patients have microbleeds. With the development of imaging technology, clinically more and more patients have found microbleeds in the brain. How these patients are treated with antithrombotic drugs is not yet clear and is in urgent need of evidence. There are only a few prospective cohort studies to determine whether antithrombotic therapy increases the risk of intracranial hemorrhage in ischemic stroke patients with CMBs, but the results are uncertain. More importantly, whether antithrombotic therapy increases the incidence of the emerging CMBs, and whether the change of increased microbleeds is associated with increased intracranial hemorrhage has not been reported.
<P>PROBLEM TO BE SOLVED: To provide an antivirus agent being nontoxic and friendly to the environment and a human body, and abundantly available as a part of effective utilization of wastes, and to provide an antivirus material, e.g. a mask, a filter or a feedstuff comprising the antivirus agent.  <P>SOLUTION: Problems are solved with the antivirus agent characterized by comprising a fine fired pulverized material from a shell. Furthermore, the fine fired pulverized material is prepared by firing and pulverizing a shell or a roughly crushed shell. The volume-average particle diameter of the fine fired pulverized material is particularly ≤15 μm. In the antivirus agent, the shell is preferably a shell of a scallop.  <P>COPYRIGHT: (C)2008,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide an antimicrobial composition obtained by using a plant as a raw material, highly safe to human beings, and having excellent antimicrobial activities; to provide a preservative and a method of pasteurization and inhibition of the proliferation of microorganisms by using the antimicrobial composition; and to provide a food, a cosmetic and a medicine with excellent preservability, using the antimicrobial composition.  <P>SOLUTION: The antimicrobial composition uses Crepidiastrum lanceolatum Nakai as a raw material for the antimicrobial composition. Preferably, at least one kind of the leaf part, the stem part and the root part of the Crepidiastrum lanceolatum Nakai is used as the raw material. More preferably at least one kind of extracts of the leaf part, the stem part and the root part of the Crepidiastrum lanceolatum Nakai is used as the raw material. The antimicrobial composition is used as the preservative for the food, the cosmetic or the medicine. The antimicrobial composition can be used in combination with other antimicrobial agents.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE: Many atrial fibrillation (AF) patients use cardiovascular medications for indications other than AF. These medications can affect morbidity and mortality. We aim to investigate the characteristics of AF patients who use different medication classes and their clinical course.
METHODS: We collected data from the prospective, multicenter registry, JoFib study. We identified classes of non-AF medications (medications not used for rate control, rhythm control, or anticoagulation), described demographic and clinical characteristics, and investigated AF-related outcomes according to these medication classes.
RESULTS: From a total of 2020 patients, five classes of cardiovascular non-AF medications were identified, aspirin, P2Y12 inhibitors, ACE inhibitors/ARBs, statins, and diuretics. The most commonly used non-AF medications were diuretics and ACE inhibitors/ARBs (39.2%, and 39%, respectively). 51% of AF patients took more than one non-AF medication. Multivariable Cox regression analysis demonstrated that ACE inhibitor/ARB therapy independently reduced the risks of all-cause mortality and cardiovascular mortality (aHR 0.50, 95%CI 0.37-0.68; aHR 0.51, 95%CI 0.34-0.75, respectively) and that statin therapy reduced the risk of cardiovascular mortality (aHR 0.68, 95%CI 0.48-0.98) in AF patients. Multivariable logistic regression analysis demonstrated a protective effect of statin therapy against the secondary outcome, clinically relevant non-major bleeding (CRNMB) (adjusted OR 0.62 95%CI 0.42-0.94).
CONCLUSION: Our findings suggest a protective effect of ACE inhibitors/ARBs against all-cause and cardiovascular mortality, statins against cardiovascular mortality, and CRNMB in patients with AF. Accordingly, these medications should be encouraged in patients with AF when indicated. Additionally, future research should explore whether these medications should be offered to AF patients more routinely. The study was registered with Clinicaltrials.gov (unique identifier number: NCT03917992, Registration date:14/4/2019).
The disclosure pertains to a medicinal preparation having a mixture of diarylheptanoid complexes and essential oil of turmeric embedded in diarylheptanoid metal complex. It also discloses a method of preparation in which the complex is formed by the reaction of diarylheptanoids with a cation in the presence of oil. Diarylheptanoid metal complexes with embedded oil show improvement in the general health of avians and mammals. Improvements in avians and mammals health include reduced mortality, improved weight gain, improved meat quality, improved bone density, improved eggshell thickness, improved immunomodulatory activity, improved liver conditions, and reduced occurrence of drug- induced dyslipidaemia. It is also found that said medicinal preparation is very effective in the prevention of the incidence of udder inflammation and in the treatment of hypocalcemia, Alzheimer's disease, and stress related issues. It has antioxidant activity as well as improved analgesic properties.
Objective: To summarize and analyze the clinical features, treatment, and prognosis of pulmonary artery stenosis post-lung transplantation. Methods: A 62-year-old male patient was admitted to the hospital with a cough and chest tightness of over a year's duration, which had worsened in the last two months, leading to the diagnosis of idiopathic pulmonary fibrosis. The clinical data were observed and reviewed post-left allograft single lung transplantation. Literature searches were conducted using the keywords "lung transplantation" "stenosis, pulmonary artery" and "postoperative complications" in CNKI, Wanfang Medical Network, and PubMed databases up to December 2022. Results: On January 26, 2022, a left allograft single lung transplantation was performed under general anesthesia. Postoperatively, extracorporeal membrane oxygenation and mechanical ventilation were successfully weaned off at 22 hours and 2 days, respectively, with transfer from the intensive care unit 12 days after surgery. PaO2 and PaCO2 were 50 mmHg and 40 mmHg after deoxygenation. Both pulmonary CT angiography and ventilatory-perfusion imaging indicated stenosis of the left pulmonary anastomosis. Balloon dilation and pulmonary artery stenting were performed, with PaO2 and PaCO2 improving to 87 mmHg and 42 mmHg, respectively. The patient was discharged 102 days post-surgery, and was followed up for 1 year, with a good prognosis. Additionally, 36 related articles were retrieved, encompassing 69 cases with a median age of 53 years (38.5-59.0 years). Of these, 27.54% (19/69) were diagnosed with idiopathic pulmonary fibrosis, 46.38% (32/69) underwent single lung transplantation, with the primary clinical symptom being hypoxemia in 71.01% (49/69) cases. Left pulmonary artery anastomotic stenosis was observed in 43.48% (30/69), with 65.22% (45/69) being diagnosed in the late postoperative period. Interventional therapy was performed to 44.93% (31/69), with a mortality rate of 21.74% (15/69). Conclusions: The primary clinical manifestation of post-lung transplantation pulmonary artery stenosis is hypoxemia and can be diagnosed by pulmonary artery CT angiography, transesophageal echocardiography, and pulmonary angiography. Early diagnosis can significantly reduce mortality, and interventional therapy is an effective treatment for severe pulmonary artery stenosis post-lung transplantation.
Although immune checkpoint inhibitors have revolutionized the treatment of several advanced solid cancers, in colorectal cancer, the transformative benefit of these innovative medicines is currently limited to those with deficient mismatch repair or high microsatellite instability. Tumor mutational burden (TMB) has emerged as a potential predictor of immunotherapy benefit, but the lack of standardization in its assessment and reporting has hindered the introduction of this biomarker in routine clinical practice. Here, we compiled 45 colorectal cancer studies utilizing numerical thresholds for high-TMB. In this group of studies, TMB cut-offs ranged from 6.88 to 41 mut/Mb and were most often set at 10, 17, or 20 mut/Mb. Additionally, we observed divergent TMB definitions and inconsistent disclosure of specific methodological details, which collectively emphasize the substantial lack of harmonization within the field. Ongoing efforts to harmonize TMB assessment will be critical to validate TMB as a predictive marker of immunotherapy response.
This is a study that will have 1 screening visit and 9 study visits. Subjects will come to the screening visit for blood chemistry, health questionnaire and speak to the coordinator. Each subject passing inclusion/exclusion will go on to eat purple rice for 4 weeks and brown rice for 4 weeks. The 4-week feeding periods will be balanced and assigned randomly. The subjects will report to the metabolic kitchen to pick up their supply of 14 frozen rice dishes each week in a container and return the empty containers as a measure of compliance. At the end of each 4-week feeding period, subjects will come to the inpatient unit fasting from 9pm the prior night except for water. Subjects will have an intravenous line placed and fasting blood will be drawn for chemistry. Subjects will then be given glucose to drink and blood will be drawn from then IV line for glucose and insulin at time listed in the consent.
Sepsis is characterized by a metabolic disorder of amino acid occurs in the early stage; however, the profile of serum amino acids and their alterations associated with the onset of sepsis remain unclear. Thus, our objective is to identify the specific kinds of amino acids as diagnostic biomarkers in pediatric patients with sepsis. Serum samples were collected from patients with sepsis admitted to the pediatric intensive care unit (PICU) between January 2019 and December 2019 on the 1st, 3rd and 7th day following admission. Demographic and laboratory variables were also retrieved from the medical records specified times. Serum amino acid concentrations were detected by UPLC-MS/MS system. PLS-DA (VIP > 1.0) and Kruskal-Wallis test (p < 0.05) were employed to identify potential biomarkers. Spearman's rank correlation analysis was conducted to find the potential association between amino acid levels and clinical features. The diagnostic utility for pediatric sepsis was assessed using receiver operating characteristic (ROC) curve analysis. Most of amino acid contents in serum were significantly decreased in patients with sepsis, but approached normal levels by the seventh day post-diagnosis. Threonine (THR), lysine (LYS), valine (VAL) and alanine (ALA) emerged as potential biomarkers related for sepsis occurrence, though they were not associated with PELOD/PELOD-2 scores. Moreover, alterations in serum THR, LYS and ALA were linked to complications of brain injury, and serum ALA levels were also related to sepsis-associated acute kidney injury. Further analysis revealed that ALA was significantly correlated with the Glasgow score, serum lactate and glucose levels, C-reactive protein (CRP), and other indicators for liver or kidney dysfunction. Notably, the area under the ROC curve (AUC) for ALA in distinguishing sepsis from healthy controls was 0.977 (95% CI: 0.925-1.000). The serum amino acid profile of children with sepsis is significantly altered compared to that of healthy controls. Notably, ALA shows promise as a potential biomarker for the early diagnosis in septic children.
A computer device obtains a plurality of medical images. The device generates a texture image based on image data of a region of interest in the medical images. The device extracts a local feature from the texture image using a first network model. The device extracts a global feature from the medical images using a second network model. The device fuses the extracted local feature and the extracted global feature to form a fused feature. The device performs image classification based on the fused feature.
The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
The invention relates to highly pure, crystalline, stable compounds of 3,3-diphenylpropylamine derivatives, in the form of their salts of general formula (I), a method for production of highly pure, stable, intermediate products of general formula (1). The compound of general formula (III) is decomposed by hydrogenation agent in order to produce the compound of general formula (VI) that is changed by acylation agent into the compound of the general formula (A) and that is changed with help of physiologically compatible inorganic or organic acid into the compound of general formula (I). The method is particularly characterized by regio- and chemo-selectivity and high yields and provides salts of phenolic monoesters of 3,3-diphenylpropylamines, which are particularly suitable for application in technical pharmaceutic formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4- hydroxymethylphenyl isobutyrate hydrogenfumarate and R-(+)-2-(3- diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl isobutyrate hydrochloride hydrate. The method further provides essential, stable, crystalline intermediate products for the production of the above salts.; A preferred intermediate product is R-(-)-3-(3-diisopropylaminophenylpropyl)-4-hydroxybenzoic acid methyl ester.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”.

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against C. difficile colitis.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of therapy with clindamycin.